Publicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Oncológicas (28)

2022

  1. Multi-omic alterations of the SWI/SNF complex define a clinical subgroup in lung adenocarcinoma

    Clinical Epigenetics, Vol. 14, Núm. 1

2021

  1. ALK-negative anaplastic large cell lymphoma: Features and outcomes of 235 patients from the International T-Cell Project

    Blood Advances, Vol. 5, Núm. 3

2020

  1. Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL

    Leukemia, Vol. 34, Núm. 10, pp. 2722-2735

  2. The value of lncRNA FENDRR and FOXF1 as a prognostic factor for survival of lung adenocarcinoma

    Oncotarget, Vol. 11, Núm. 13, pp. 1172-1185

2010

  1. Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer

    Journal of Pathology, Vol. 222, Núm. 1, pp. 89-98

2009

  1. The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer

    Human Molecular Genetics, Vol. 18, Núm. 7, pp. 1343-1352

2008

  1. Erratum: Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer (Epigenetics vol. 3(2) (64-68))

    Epigenetics

  2. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification

    Journal of Pathology, Vol. 214, Núm. 3, pp. 347-356

  3. Frequent BRG1/SMARCA4-Inactivating mutations in human lung cancer cell lines

    Human Mutation, Vol. 29, Núm. 5, pp. 617-622

  4. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer

    Epigenetics, Vol. 3, Núm. 2, pp. 64-68

2007

  1. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer

    Oncogene, Vol. 26, Núm. 11, pp. 1616-1625

  2. Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas

    Blood, Vol. 110, Núm. 9, pp. 3345-3351

  3. In reply [2]

    Journal of Clinical Oncology

2006

  1. A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers

    Human Mutation, Vol. 27, Núm. 3, pp. 242-248

  2. Allelic expression and quantitative RT-PCR study of TAp73 and ΔNp73 in non-Hodgkin's lymphomas

    Leukemia Research, Vol. 30, Núm. 2, pp. 170-177

  3. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy

    Journal of Clinical Oncology, Vol. 24, Núm. 26, pp. 4333-4339

  4. Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: A Spanish case-control study

    International Journal of Cancer, Vol. 119, Núm. 2, pp. 467-471

2005

  1. Differential expression of NF-κB pathway genes among peripheral T-cell lymphomas

    Leukemia, Vol. 19, Núm. 12, pp. 2254-2263

  2. Expression of the NF-κB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively

    Journal of Pathology, Vol. 206, Núm. 2, pp. 123-134

  3. Identification of amplified and highly expressed genes in amplicons of the T-cell line huT78 detected by cDNA microarray CGH

    Molecular Cancer, Vol. 4